Implandata Ophthalmic Products GmbH, based in Hannover, Germany and led by CEO Max Ostermeier, develops the CE‑marked EYEMATE system for continuous intraocular pressure (IOP) monitoring. The EYEMATE system consists of a surgically implantable micro‑sensor and a patient hand‑held device that powers the sensor and transmits real‑time data via the internet to eye care specialists and patients. The company is ISO 13485 certified and is expanding its product portfolio with different sensor implant versions to address varied glaucoma patient needs. Implandata envisions implantation in conjunction with cataract, glaucoma or corneal surgery and eventually as a stand‑alone procedure. Financially, the company has completed a first close of its Series C at a mid‑single‑digit million euro level and plans to raise an upper‑end single‑digit million euro amount to complete the round by fall 2018. Implandata Ophthalmic Products (IOP) develops a minimally invasive intraocular micro-sensor paired with a handheld unit that lets patients repeatedly and on-demand measure intraocular pressure at home. The system is designed to enable early diagnosis of glaucoma, monitor disease progression and therapy, and help protect patients against blindness. IOP plans to embed the device in a telemedical diagnostic platform to connect patients with doctors and improve compliance. The company's first product—the intraocular sensor—is currently in a CE approval trial, with data expected within the next 18 months. IOP is led by Managing Director Max Ostermeier. Financially, the company has completed a €1.6m second closing of a €3.0m Series A, following a €1.4m first closing in December 2011, and intends to use the new capital to run a CE trial to achieve early market access. Implandata Ophthalmic Products has developed a system that enables continuous measurement of intraocular pressure in glaucoma patients using a minimally invasive micro-sensor and a hand-held unit. The company has begun the CE approval process and has carried out initial implantations. It expects market entry within the next 12 to 18 months. The business is led by co-founder and Managing Director Max G. Ostermeier. Financially, Implandata has secured external capital to support development and regulatory steps. The company is also in advanced talks for a second closing round to be completed by the end of March 2012. Implandata Ophthalmic Products GmbH is a Hanover, Germany–based startup developing a diagnostic system to continuously monitor intraocular pressure for glaucoma patients. The company’s implantable monitoring system is intended to help specialists recognize glaucoma progression and protect patients from blindness. The device can be used telemedically. Implandata has demonstrated the system’s functionality and safety in vitro and in vivo on animals and humans. The company raised about €700,000 to support launching the system and obtaining CE approval. Management plans to use the capital to obtain CE approval and go to market by the end of 2011.

Total raised

$5M

Funding rounds

4

Latest round

Series A

Latest activity

Aug 2012